We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
PALIPERIDONE-TEVA (Teva Pharma Australia Pty Ltd)
Product name
PALIPERIDONE-TEVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
paliperidone palmitate
Registration type
New generic medicine
Indication
PALIPERIDONE-TEVA is indicated for the acute and maintenance treatment of schizophrenia in adults.
Registration process
First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine